Survival outcomes of patients with extranodal natural-killer T-cell lymphoma: a prospective cohort study from the international T-cell Project.

[1]  J. Lai,et al.  Local Irradiation Sensitized Tumors to Adoptive T Cell Therapy via Enhancing the Cross-Priming, Homing, and Cytotoxicity of Antigen-Specific CD8 T Cells , 2019, Front. Immunol..

[2]  H. Matsuoka,et al.  Improved prognosis of extranodal NK/T cell lymphoma, nasal type of nasal origin but not extranasal origin , 2019, Annals of Hematology.

[3]  R. Suzuki,et al.  Advances in the treatment of extranodal NK/T-cell lymphoma, nasal type. , 2018, Blood.

[4]  C. Ki,et al.  Significance of circulating Epstein-Barr virus DNA monitoring after remission in patients with extranodal natural killer T cell lymphoma , 2018, Annals of Hematology.

[5]  J. Itami,et al.  Treatments and Outcomes of Patients With Extranodal Natural Killer/T-Cell Lymphoma Diagnosed Between 2000 and 2013: A Cooperative Study in Japan. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  P. Khong,et al.  PD1 blockade with low-dose nivolumab in NK/T cell lymphoma failing l-asparaginase: efficacy and safety , 2017, Annals of Hematology.

[7]  Zenggang Pan,et al.  Extranodal NK/T Cell Lymphoma, Nasal Type (ENKTL-NT): An Update on Epidemiology, Clinical Presentation, and Natural History in North American and European Cases , 2016, Current Hematologic Malignancy Reports.

[8]  Y. Shentu,et al.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. , 2016, The New England journal of medicine.

[9]  Sin-Ho Jung,et al.  A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis. , 2016, The Lancet. Oncology.

[10]  J. Choi,et al.  Induction treatment with SMILE and consolidation with autologous stem cell transplantation for newly diagnosed stage IV extranodal natural killer/T-cell lymphoma patients , 2014, Annals of Hematology.

[11]  R. Suzuki,et al.  Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  P. Gaulard,et al.  Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study. , 2011, Blood.

[13]  H. Gill,et al.  Extranodal Natural-Killer/T-Cell Lymphoma, Nasal Type , 2010, Advances in hematology.

[14]  Sang‐wook Lee,et al.  Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  K. Ohshima,et al.  Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  R. Liang.  Advances in the management and monitoring of extranodal NK/T‐cell lymphoma, nasal type , 2009, British journal of haematology.

[17]  D. Weisenburger,et al.  Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project. , 2009, Blood.

[18]  D. Weisenburger,et al.  International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Sigrid Stroobants,et al.  Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  M. Hareyama,et al.  Analyses of dose-response in radiotherapy for patients with mature T/NK-cell lymphomas according to the WHO classification. , 2006, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[21]  Keunchil Park,et al.  Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Shulian Wang,et al.  Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Ji Yeun Kim,et al.  Therapeutic Outcome of Extranodal NK/T-Cell Lymphoma Initially Treated with Chemotherapy Result of Chemotherapy in NK/T-Cell Lymphoma , 2003, Acta oncologica.

[24]  J Crowley,et al.  Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. , 1999, Statistics in medicine.